loading...| Preferred Name |
Vismodegib |
|
| Synonyms |
Hedgehog Antagonist GDC-0449 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide Erivedge GDC-0449 VISMODEGIB Vismodegib |
|
| Definitions |
An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C74038 |
|
| Accepted_Therapeutic_Use_For |
basal cell carcinoma |
|
| ALT_DEFINITION |
A substance being studied in the treatment of cancer. It blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. It is a type of Hedgehog signaling pathway antagonist. |
|
| CAS_Registry |
879085-55-9 |
|
| Chemical_Formula |
C19H14Cl2N2O3S |
|
| code |
C74038 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. |
|
| Display_Name |
Vismodegib |
|
| FDA_UNII_Code |
25X868M3DS |
|
| FULL_SYN |
Hedgehog Antagonist GDC-0449 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide Erivedge GDC-0449 VISMODEGIB Vismodegib |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Vismodegib |
|
| Legacy Concept Name |
Hedgehog_Antagonist_GDC-0449 |
|
| Maps_To |
Vismodegib |
|
| NCI_Drug_Dictionary_ID |
586417 |
|
| PDQ_Closed_Trial_Search_ID |
586417 |
|
| PDQ_Open_Trial_Search_ID |
586417 |
|
| Preferred_Name |
Vismodegib |
|
| prefixIRI |
Thesaurus:C74038 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2348949 |
|
| subClassOf |